Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

As Orphan Drugs Gain More Attention, FDA Releases Development Guidance

Aug 14 2015

• By Derrick Gingery

Related Content

Rare Disease R&D: FDA To Use NIH Registry For Natural History Studies

Apr 16 2012

In Manufacturing, Absence Of Evidence Is Not Evidence Of Absence, FDA Tells BioMarin

Nov 19 2014

Rare Diseases Need Ongoing Natural History Studies To Speed Trials, FDA Says

Nov 14 2011

PDUFA VI: Price Tag For Patient Experience Data Validation May Go Up

Jun 18 2015

Biomarkers In Orphan Studies Still Need Past Experience, FDA Says

May 27 2013

Related Companies

BioMarin Pharmaceutical Inc.

Additional Topics

United States Clinical Trials Manufacturing Drug Approval Standards Regulation Research & Development BioPharmaceutical

More from United States

More from North America

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window